MedTrace Logo

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

NCT00002598 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-06-25

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Interferon alfa may interfere with the growth of cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and interferon alfa in treating patients with chronic myelogenous leukemia.

Conditions

Interventions

BIOLOGICAL

recombinant interferon alfa

BIOLOGICAL

sargramostim

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

etoposide

DRUG

methotrexate

DRUG

mitoxantrone hydrochloride

PROCEDURE

bone marrow ablation with stem cell support

RADIATION

radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Mark Adam Weiss, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-06-30
Primary Completion
2004-06-30
Completion
2004-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002598 on ClinicalTrials.gov